TY - JOUR
T1 - PRO Spective evaluation of chronic pancreatitis for epid emiologic and translational studies
T2 - Rationale and study design for PROCEED from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer
AU - Yadav, Dhiraj
AU - Park, Walter G.
AU - Fogel, Evan L.
AU - Li, Liang
AU - Chari, Suresh T.
AU - Feng, Ziding
AU - Fisher, William E.
AU - Forsmark, Christopher E.
AU - Jeon, Christie Y.
AU - Habtezion, Aida
AU - Hart, Phil A.
AU - Hughes, Steven J.
AU - Othman, Mohamed O.
AU - Rinaudo, Jo Ann S.
AU - Pandol, Stephen J.
AU - Tirkes, Temel
AU - Serrano, Jose
AU - Srivastava, Sudhir
AU - Van Den Eeden, Stephen K.
AU - Whitcomb, David C.
AU - Topazian, Mark
AU - Conwell, Darwin L.
N1 - Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.
AB - Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP-controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.
KW - alcohol
KW - biorepository
KW - cohort
KW - genetic
KW - pancreas
KW - tobacco
UR - http://www.scopus.com/inward/record.url?scp=85055078667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055078667&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001170
DO - 10.1097/MPA.0000000000001170
M3 - Article
C2 - 30325862
AN - SCOPUS:85055078667
SN - 0885-3177
VL - 47
SP - 1229
EP - 1238
JO - Pancreas
JF - Pancreas
IS - 10
ER -
